Innovation is accelerating through bispecifics and dual payload strategies | Emerging ADC development approaches such as ...

The PrIMAVeRa project develops a platform to evaluate how mAbs can combat AMR by reducing antibiotic use and providing ...

Viridian Therapeutics focuses on precision-driven biological research targeting rare and complex autoimmune conditions.

According to research by SNS Insider, the U.S. Antibody Discovery Market is projected to grow at a CAGR of 8.13%, fueled by expanding biologics pipelines, strategic collaborations, and increased ...

Topline final safety and efficacy results for the full 36 weeks of treatment from all participants will be available in ...

Latozinemab failure, with Nivisnebart Phase 2 data as the next key catalyst. Click here to read more about ALEC stock.

Curious about the animals most often used in research? Get to know the top five—like mice, rabbits, and goats—and the roles ...

UCSF's Dr Laura Huppert explores a phase 2 trial assessing ARX788's safety and efficacy for HER2-low breast cancer patients, ...

ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics and vaccines targeting toxic misfolded proteins in ...

We came across a bullish thesis on Alvotech on Ridire Research’s Substack. In this article, we will summarize the bulls’ thesis on ALVO.

Troy’s gut instinct told him: don’t give in—get busy. He began working closely on treatment with his oncologist, as well as ...

LINKER-MM4 trial shows linvoseltamab monotherapy achieves a 79% overall response rate in newly diagnosed MM patients, with 92 ...